Brian T. Hill
Experienced in IgG4-Related Disease

Dr. Brian T. Hill

Hematology Oncology | Hematology | Oncology
Cleveland Clinic
Cleveland Clinic Main Campus
10201 Carnegie Avenue, 
Cleveland, OH 
On Staff At
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
30 Years of Experience

Experienced in IgG4-Related Disease
Cleveland Clinic
Cleveland Clinic Main Campus
10201 Carnegie Avenue, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Hill is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Hill has been practicing medicine for over 30 years and is rated as an Experienced provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 222 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Dartmouth College, 1996.0
Residency
University of Chicago Hospitals
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OH
Fellowships
Cleveland Clinic
Hospital Affiliations
Hillcrest Hospital
Cleveland Clinic Avon Hospital
Cleveland Clinic
Akron General Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

Cleveland Clinic Main Campus
10201 Carnegie Avenue, Cleveland, OH 44106
Call: 866-223-8100

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


13 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
Phase I Trial of Loncastuximab Tesirine and Venetoclax for Treatment of Relapsed/ Refractory Non-Hodgkin Lymphoma
Phase I Trial of Loncastuximab Tesirine and Venetoclax for Treatment of Relapsed/ Refractory Non-Hodgkin Lymphoma
Enrollment Status: Recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Loncastuximab Tesirine, Venetoclax
Study Phase: Phase 1
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
A Phase I Trial of Venetoclax in Combination With BEAM Conditioning Regimen for Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase I Trial of Venetoclax in Combination With BEAM Conditioning Regimen for Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drug: Venetoclax
Study Phase: Phase 1
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2024
Intervention Type: Biological
Study Drug: NKX019
Study Phase: Phase 1
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Procedure, Other
A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell Lymphoma
A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 29, 2024
Intervention Type: Drug, Biological
Study Drugs: Carfilzomib, Rituximab, Cyclophosphamide, Doxorubicin hydrochloride, Vincristine sulfate, Prednisone, Pegfilgrastim, Acyclovir
Study Phase: Phase 1/Phase 2
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Enrollment Status: Terminated
Publish Date: November 18, 2023
Intervention Type: Biological, Drug
Study Drugs: Brexucabtagene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Enrollment Status: Completed
Publish Date: January 31, 2023
Intervention Type: Drug, Genetic
Study Drugs: Fludarabine, Cyclophosphamide, Anti-CD20 CAR-T Cells
Study Phase: Phase 1/Phase 2
A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma
A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Rituximab
Study Phase: Phase 1/Phase 2
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

222 Total Publications

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.
Journal: Leukemia & lymphoma
Published: July 09, 2025
View All 222 Publications
Similar Doctors
Shahzad Raza
Experienced in IgG4-Related Disease
Dr. Shahzad Raza
Hematology Oncology | Hematology | Oncology
Experienced in IgG4-Related Disease
Dr. Shahzad Raza
Hematology Oncology | Hematology | Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.3 miles away)
866-223-8100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shahzad Raza is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Raza is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Primary Amyloidosis, Bone Marrow Aspiration, and Tissue Biopsy.

Experienced in IgG4-Related Disease
Dr. Mukesh C. Bhatt
Hematology Oncology | Hematology | Oncology
Experienced in IgG4-Related Disease
Dr. Mukesh C. Bhatt
Hematology Oncology | Hematology | Oncology

University Primary Care Practices Inc

970 E Washington St, Suite 4d, 
Medina, OH 
 (27.5 miles away)
330-722-5420
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Mukesh Bhatt is a Hematologist Oncology specialist and a Hematologist in Medina, Ohio. Dr. Bhatt is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Familial Colorectal Cancer, Anemia, Thrombocytopenia, and Childhood Iron Deficiency Anemia. Dr. Bhatt is currently accepting new patients.

Jason Valent
Experienced in IgG4-Related Disease
Dr. Jason Valent
Hematology Oncology | Hematology | Oncology
Experienced in IgG4-Related Disease
Dr. Jason Valent
Hematology Oncology | Hematology | Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jason Valent is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Valent is rated as an Elite provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration.

VIEW MORE IGG4-RELATED DISEASE DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hill's expertise for a condition
ConditionClose
  • Elite
  • B-Cell Lymphoma
    Dr. Hill is
    Elite
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Chronic B-Cell Leukemia (CBCL)
    Dr. Hill is
    Elite
    . Learn about Chronic B-Cell Leukemia (CBCL).
    See more Chronic B-Cell Leukemia (CBCL) experts
  • Chronic Lymphocytic Leukemia (CLL)
    Dr. Hill is
    Elite
    . Learn about Chronic Lymphocytic Leukemia (CLL).
    See more Chronic Lymphocytic Leukemia (CLL) experts
  • Diffuse Large B-Cell Lymphoma (DLBCL)
    Dr. Hill is
    Elite
    . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
    See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
  • Follicular Lymphoma
    Dr. Hill is
    Elite
    . Learn about Follicular Lymphoma.
    See more Follicular Lymphoma experts
  • Mantle Cell Lymphoma (MCL)
    Dr. Hill is
    Elite
    . Learn about Mantle Cell Lymphoma (MCL).
    See more Mantle Cell Lymphoma (MCL) experts
View All 8 Elite Conditions
  • Distinguished
  • Hairy Cell Leukemia (HCL)
    Dr. Hill is
    Distinguished
    . Learn about Hairy Cell Leukemia (HCL).
    See more Hairy Cell Leukemia (HCL) experts
  • Hodgkin Lymphoma
    Dr. Hill is
    Distinguished
    . Learn about Hodgkin Lymphoma.
    See more Hodgkin Lymphoma experts
  • Large-Cell Immunoblastic Lymphoma
    Dr. Hill is
    Distinguished
    . Learn about Large-Cell Immunoblastic Lymphoma.
    See more Large-Cell Immunoblastic Lymphoma experts
  • Leukemia
    Dr. Hill is
    Distinguished
    . Learn about Leukemia.
    See more Leukemia experts
  • Marginal Zone Lymphoma (MZL)
    Dr. Hill is
    Distinguished
    . Learn about Marginal Zone Lymphoma (MZL).
    See more Marginal Zone Lymphoma (MZL) experts
  • Primary Mediastinal B-Cell Lymphoma (PMBCL)
    Dr. Hill is
    Distinguished
    . Learn about Primary Mediastinal B-Cell Lymphoma (PMBCL).
    See more Primary Mediastinal B-Cell Lymphoma (PMBCL) experts
View All 7 Distinguished Conditions
  • Advanced
  • Agranulocytosis
    Dr. Hill is
    Advanced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Bone Marrow Transplant
    Dr. Hill is
    Advanced
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Burkitt Lymphoma
    Dr. Hill is
    Advanced
    . Learn about Burkitt Lymphoma.
    See more Burkitt Lymphoma experts
  • Chronic Familial Neutropenia
    Dr. Hill is
    Advanced
    . Learn about Chronic Familial Neutropenia.
    See more Chronic Familial Neutropenia experts
  • Classical Hodgkin Lymphoma
    Dr. Hill is
    Advanced
    . Learn about Classical Hodgkin Lymphoma.
    See more Classical Hodgkin Lymphoma experts
  • Febrile Neutropenia
    Dr. Hill is
    Advanced
    . Learn about Febrile Neutropenia.
    See more Febrile Neutropenia experts
View All 16 Advanced Conditions
  • Experienced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Hill is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Hill is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Hill is
    Experienced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Hill is
    Experienced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Anaplastic Large Cell Lymphoma
    Dr. Hill is
    Experienced
    . Learn about Anaplastic Large Cell Lymphoma.
    See more Anaplastic Large Cell Lymphoma experts
  • Anemia
    Dr. Hill is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved